Free Trial

iRadimed (IRMD) Financials

iRadimed logo
$69.93 +0.96 (+1.39%)
Closing price 04:00 PM Eastern
Extended Trading
$69.99 +0.06 (+0.09%)
As of 04:10 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Annual Income Statements for iRadimed

Annual Income Statements for iRadimed

This table shows iRadimed's income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders
2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Consolidated Net Income / (Loss)
2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Net Income / (Loss) Continuing Operations
2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Total Pre-Tax Income
3.02 12 11 1.40 6.20 9.04 -0.62 9.84 16 22 24
Total Operating Income
3.07 12 11 1.29 6.00 8.65 -0.76 9.82 16 20 22
Total Gross Profit
12 26 26 18 23 30 24 32 41 50 56
Total Revenue
16 32 32 23 30 39 32 42 53 66 73
Operating Revenue
16 32 32 23 30 39 32 42 53 66 73
Total Cost of Revenue
3.40 5.84 6.15 5.57 7.21 8.82 8.14 9.76 12 15 17
Operating Cost of Revenue
3.40 5.84 6.15 5.57 7.21 8.82 8.14 9.76 12 15 17
Total Operating Expenses
9.18 14 15 16 17 21 24 22 26 30 34
Selling, General & Admin Expense
4.82 7.77 8.80 9.00 8.71 10 12 9.77 11 15 16
Marketing Expense
3.30 4.71 5.28 5.50 7.00 9.17 10 11 13 12 16
Research & Development Expense
1.07 1.76 1.35 1.72 1.52 1.43 1.90 1.91 2.28 2.86 2.83
Total Other Income / (Expense), net
-0.05 0.12 0.03 0.11 0.19 0.40 0.14 0.02 0.55 1.70 2.31
Other Income / (Expense), net
-0.05 0.12 0.03 0.11 0.19 0.40 0.14 0.02 0.55 1.70 2.31
Income Tax Expense
0.97 4.10 3.74 0.90 -0.11 -0.59 -1.99 0.51 3.35 4.55 5.04
Basic Earnings per Share
$0.23 $0.68 $0.67 $0.05 $0.59 $0.85 $0.11 $0.76 $1.02 $1.36 $1.52
Weighted Average Basic Shares Outstanding
8.74M 11.00M 10.82M 10.64M 10.76M 11.28M 12.12M 12.35M 12.56M 12.60M 12.67M
Diluted Earnings per Share
$0.20 $0.60 $0.60 $0.04 $0.52 $0.78 $0.11 $0.74 $1.02 $1.35 $1.50
Weighted Average Diluted Shares Outstanding
10.22M 12.56M 11.99M 11.72M 12.11M 12.28M 12.44M 12.59M 12.64M 12.72M 12.78M
Weighted Average Basic & Diluted Shares Outstanding
8.90M 11.10M 10.80M 10M 11.00M 11.92M 12.31M 12.56M 12.59M 12.66M 12.72M

Quarterly Income Statements for iRadimed

This table shows iRadimed's income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Income / (Loss) Attributable to Common Shareholders
3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Consolidated Net Income / (Loss)
3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Net Income / (Loss) Continuing Operations
3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Total Pre-Tax Income
4.70 4.35 5.30 6.41 5.68 5.24 6.27 6.42 6.34 5.95 7.33
Total Operating Income
4.25 4.01 4.96 5.91 5.16 4.75 5.63 5.79 5.80 5.43 6.79
Total Gross Profit
11 12 12 13 13 13 14 14 15 15 16
Total Revenue
15 15 16 17 17 18 18 18 19 20 20
Operating Revenue
15 15 16 17 17 18 18 18 19 20 20
Total Cost of Revenue
3.64 3.75 3.94 3.67 4.04 4.21 3.92 4.13 4.63 4.67 4.45
Operating Cost of Revenue
3.64 3.75 3.94 3.67 4.04 4.21 3.92 4.13 4.63 4.67 4.45
Total Operating Expenses
6.97 7.71 7.22 6.93 8.25 8.64 8.38 8.40 8.96 9.41 9.17
Selling, General & Admin Expense
2.70 3.92 3.31 3.62 4.27 3.99 4.10 3.97 3.87 4.61 4.28
Marketing Expense
3.67 0.79 2.95 2.86 5.54 3.83 3.48 3.80 7.52 4.18 4.01
Research & Development Expense
0.60 3.00 0.96 0.45 -1.56 0.82 0.80 0.64 -2.44 0.62 0.88
Total Other Income / (Expense), net
0.45 0.34 0.34 0.50 0.52 0.50 0.64 0.63 0.54 0.51 0.54
Other Income / (Expense), net
0.45 0.34 0.34 0.50 0.52 0.50 0.64 0.63 0.54 0.51 0.54
Income Tax Expense
1.03 0.94 1.12 1.34 1.14 1.11 1.37 1.37 1.20 1.26 1.55
Basic Earnings per Share
$0.29 $0.27 $0.33 $0.40 $0.36 $0.33 $0.39 $0.40 $0.40 $0.37 $0.45
Weighted Average Basic Shares Outstanding
12.56M 12.59M 12.60M 12.60M 12.60M 12.66M 12.66M 12.67M 12.67M 12.71M 12.72M
Diluted Earnings per Share
$0.29 $0.27 $0.33 $0.40 $0.35 $0.32 $0.38 $0.40 $0.40 $0.37 $0.45
Weighted Average Diluted Shares Outstanding
12.64M 12.69M 12.72M 12.74M 12.72M 12.75M 12.76M 12.78M 12.78M 12.83M 12.84M
Weighted Average Basic & Diluted Shares Outstanding
12.59M 12.59M 12.60M 12.61M 12.66M 12.66M 12.67M 12.67M 12.72M 12.72M 12.72M

Annual Cash Flow Statements for iRadimed

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents
6.99 9.91 -1.65 0.49 9.82 15 6.59 12 -4.04 -8.20 2.47
Net Cash From Operating Activities
2.92 7.65 9.41 3.42 7.38 10 5.82 11 10 13 26
Net Cash From Continuing Operating Activities
2.59 7.65 9.41 3.42 7.38 10 5.82 11 10 13 26
Net Income / (Loss) Continuing Operations
2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Consolidated Net Income / (Loss)
2.05 7.53 7.21 0.50 6.30 9.63 1.37 9.33 13 17 19
Depreciation Expense
0.15 0.81 0.96 1.31 1.11 1.24 1.34 1.41 0.67 0.77 0.82
Non-Cash Adjustments To Reconcile Net Income
0.69 1.34 2.04 2.75 1.93 1.93 3.90 1.62 1.59 2.61 2.52
Changes in Operating Assets and Liabilities, net
-0.30 -2.03 -0.80 -1.14 -1.97 -2.57 -0.79 -1.07 -5.02 -7.11 3.05
Net Cash From Investing Activities
-8.30 -0.06 -1.94 -1.02 1.52 3.20 0.25 0.65 -1.37 -8.01 -8.82
Net Cash From Continuing Investing Activities
-8.30 -0.06 -1.94 -1.02 1.52 3.20 0.25 0.65 -1.37 -8.01 -8.82
Purchase of Property, Plant & Equipment
-0.61 -0.31 -1.52 -0.82 -0.26 -0.49 -0.64 -0.74 -1.87 -8.01 -8.82
Net Cash From Financing Activities
13 2.33 -9.12 -1.90 0.93 2.02 0.52 0.02 -13 -14 -14
Net Cash From Continuing Financing Activities
13 2.33 -9.12 -1.90 0.93 2.02 0.52 0.02 -13 -14 -14
Payment of Dividends
- - - - - - - 0.00 -13 -13 -14
Other Financing Activities, net
0.17 1.73 0.60 -0.16 0.93 -0.47 -1.21 0.02 -0.15 -0.43 -0.66
Cash Income Taxes Paid
1.18 2.70 3.39 1.21 1.38 0.01 0.00 0.97 1.71 5.35 6.51

Quarterly Cash Flow Statements for iRadimed

This table details how cash moves in and out of iRadimed's business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Net Change in Cash & Equivalents
2.37 -15 3.05 0.92 3.02 -4.64 3.41 3.19 0.51 -1.90 2.66
Net Cash From Operating Activities
3.04 4.65 3.51 1.39 3.91 3.88 6.64 9.12 5.99 4.29 7.75
Net Cash From Continuing Operating Activities
3.06 4.65 3.51 1.39 3.91 3.88 6.64 9.03 6.08 4.29 7.75
Net Income / (Loss) Continuing Operations
3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Consolidated Net Income / (Loss)
3.67 3.41 4.18 5.07 4.54 4.14 4.90 5.05 5.15 4.69 5.77
Depreciation Expense
-0.69 0.18 0.19 0.19 0.21 0.23 0.20 0.20 0.19 0.19 0.21
Non-Cash Adjustments To Reconcile Net Income
0.56 0.81 0.65 0.57 0.59 0.63 0.74 0.02 1.13 0.77 0.76
Changes in Operating Assets and Liabilities, net
-0.48 0.25 -1.50 -4.43 -1.42 -1.11 0.80 3.75 -0.40 -1.36 1.00
Net Cash From Investing Activities
-0.47 -6.56 -0.38 -0.44 -0.63 -0.48 -1.27 -4.01 -3.06 -3.92 -2.82
Net Cash From Continuing Investing Activities
-0.47 -6.56 -0.38 -0.44 -0.63 -0.48 -1.27 -4.01 -3.06 -3.92 -2.82
Purchase of Property, Plant & Equipment
-0.47 -6.56 -0.38 -0.44 -0.63 -0.48 -1.27 -4.01 -3.06 -3.92 -2.82
Net Cash From Financing Activities
-0.20 -13 -0.09 -0.03 -0.26 -8.04 -1.96 -1.92 -2.42 -2.28 -2.26
Net Cash From Continuing Financing Activities
-0.20 -13 -0.09 -0.03 -0.26 -8.04 -1.96 -1.92 -2.42 -2.28 -2.26
Payment of Dividends
- -13 - - - -7.98 -1.90 -1.90 -1.90 -2.16 -2.16
Other Financing Activities, net
-0.20 -0.05 -0.09 -0.03 -0.26 -0.06 -0.06 -0.02 -0.52 -0.12 -0.10
Cash Income Taxes Paid
0.95 0.00 2.76 1.38 1.22 0.19 2.82 1.45 2.06 0.01 2.34

Annual Balance Sheets for iRadimed

This table presents iRadimed's assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets
23 35 37 39 48 67 71 83 86 92 98
Total Current Assets
22 34 34 35 45 59 64 76 77 76 75
Cash & Equivalents
9.45 19 18 18 28 43 50 62 58 50 52
Accounts Receivable
1.96 3.86 3.78 3.78 4.21 7.29 4.57 5.14 13 12 11
Inventories, net
2.13 2.38 3.89 4.21 4.06 3.64 3.93 4.30 5.37 13 10
Prepaid Expenses
0.28 0.32 0.36 0.65 0.53 0.41 0.77 1.00 0.63 1.19 1.51
Current Deferred & Refundable Income Taxes
0.44 0.42 0.15 0.13 1.37 1.37 2.48 3.31 0.25 - 0.54
Plant, Property, & Equipment, net
0.79 0.91 1.46 1.87 1.87 2.05 2.12 2.07 2.40 9.29 17
Total Noncurrent Assets
0.35 0.39 1.88 2.04 2.03 5.71 5.21 4.57 5.62 6.87 6.27
Intangible Assets
0.25 0.19 0.92 0.89 0.83 0.86 0.96 1.12 2.07 2.52 3.10
Noncurrent Deferred & Refundable Income Taxes
0.08 0.09 0.79 0.95 1.09 1.66 1.27 0.77 0.70 2.12 2.82
Other Noncurrent Operating Assets
0.02 0.10 0.17 0.20 0.11 3.19 2.98 2.68 2.85 2.22 0.35
Total Liabilities & Shareholders' Equity
23 35 37 39 48 67 71 83 86 92 98
Total Liabilities
2.42 3.31 5.31 6.08 6.50 11 9.68 11 12 21 12
Total Current Liabilities
2.28 2.89 3.66 4.08 4.69 5.86 4.92 6.82 8.55 16 8.51
Accounts Payable
0.63 1.01 1.12 0.66 0.77 0.99 0.66 0.78 1.80 1.86 1.90
Accrued Expenses
0.03 0.03 0.04 0.06 0.07 0.08 0.09 0.11 0.09 0.12 0.12
Current Deferred Revenue
0.31 0.53 1.03 1.62 1.80 1.67 1.95 2.55 3.37 2.57 2.26
Current Employee Benefit Liabilities
1.24 1.29 1.04 1.51 1.80 2.17 1.71 2.81 2.87 2.78 3.77
Other Taxes Payable
0.07 0.03 0.12 0.11 0.13 0.60 0.10 0.14 0.12 0.10 0.16
Other Current Liabilities
- - 0.12 0.11 0.11 0.35 0.40 0.42 0.29 0.68 0.30
Total Noncurrent Liabilities
0.14 0.42 1.64 2.00 1.81 5.35 4.76 3.88 3.29 4.41 2.99
Noncurrent Deferred Revenue
0.14 0.42 1.64 2.00 1.81 2.63 2.31 1.68 1.38 2.79 2.99
Other Noncurrent Operating Liabilities
- - - - - 2.72 2.46 2.21 1.91 1.62 0.00
Total Equity & Noncontrolling Interests
21 32 32 33 42 56 61 72 74 71 87
Total Preferred & Common Equity
21 32 32 33 42 56 61 72 74 71 87
Total Common Equity
21 32 32 33 42 56 61 72 74 71 87
Common Stock
16 19 12 13 15 19 24 25 26 28 30
Retained Earnings
5.13 13 20 20 27 36 38 47 47 43 57

Quarterly Balance Sheets for iRadimed

This table presents iRadimed's assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q2 2022 Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025
Period end date 6/30/2022 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025
Total Assets
76 80 76 81 87 88 90 94 102 106
Total Current Assets
68 72 61 66 72 72 74 74 75 77
Cash & Equivalents
52 56 43 46 47 45 49 52 50 53
Accounts Receivable
8.38 11 12 11 13 13 12 10 13 11
Inventories, net
4.86 5.24 6.31 8.42 12 13 12 11 11 11
Prepaid Expenses
0.80 0.39 0.68 0.77 0.74 1.04 1.02 0.95 1.54 1.92
Current Deferred & Refundable Income Taxes
2.30 0.00 0.00 0.00 0.00 - - - - 0.33
Plant, Property, & Equipment, net
2.24 2.29 8.64 8.72 8.89 9.45 10 14 20 23
Total Noncurrent Assets
4.99 5.38 5.68 6.62 6.59 6.68 5.90 5.80 6.21 6.14
Intangible Assets
1.54 1.88 2.21 2.35 2.46 2.67 2.75 2.89 3.26 3.37
Noncurrent Deferred & Refundable Income Taxes
0.90 0.99 0.62 1.77 1.80 1.88 2.59 2.46 2.69 2.56
Other Noncurrent Operating Assets
2.55 2.51 2.85 2.50 2.32 2.12 0.56 0.45 0.27 0.20
Total Liabilities & Shareholders' Equity
76 80 76 81 87 88 90 94 102 106
Total Liabilities
9.83 9.77 11 12 13 12 10 11 12 12
Total Current Liabilities
6.14 5.60 6.76 7.59 7.88 7.62 7.46 8.06 8.47 8.81
Accounts Payable
0.82 0.96 1.76 2.55 2.78 1.29 1.12 1.40 2.59 1.90
Accrued Expenses
0.10 0.10 0.10 0.11 0.11 0.12 0.12 0.12 0.12 0.12
Current Deferred Revenue
2.29 1.59 2.07 1.71 1.92 2.34 2.54 2.56 2.60 3.26
Current Employee Benefit Liabilities
2.27 2.35 1.62 2.33 2.29 2.14 2.90 3.28 2.27 3.21
Other Taxes Payable
0.24 0.18 0.06 0.22 0.10 0.14 0.16 0.19 0.26 0.32
Other Current Liabilities
0.42 0.43 0.66 0.66 0.67 0.67 0.62 0.51 0.06 0.00
Total Noncurrent Liabilities
3.69 4.17 4.52 4.85 4.96 4.28 2.82 2.75 3.20 3.33
Noncurrent Deferred Revenue
1.63 2.18 2.59 3.01 3.23 2.76 2.82 2.75 3.20 3.33
Other Noncurrent Operating Liabilities
2.06 1.99 1.94 1.83 1.72 1.52 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests
66 70 64 69 75 76 80 83 90 94
Total Preferred & Common Equity
66 70 64 69 75 76 80 83 90 94
Total Common Equity
66 70 64 69 75 76 80 83 90 94
Common Stock
26 26 27 27 28 29 29 30 31 31
Retained Earnings
40 44 37 42 47 47 50 54 59 63

Annual Metrics And Ratios for iRadimed

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024
Period end date 12/31/2014 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Growth Metrics
- - - - - - - - - - -
Revenue Growth
38.03% 101.84% 2.86% -28.97% 31.88% 26.54% -17.65% 31.83% 27.48% 23.00% 11.71%
EBITDA Growth
8.33% 292.93% -4.29% -77.28% 169.94% 40.85% -92.98% 1,457.33% 49.88% 33.54% 11.51%
EBIT Growth
8.39% 285.59% -5.86% -87.25% 343.81% 45.92% -106.82% 1,694.53% 64.50% 34.35% 11.67%
NOPAT Growth
7.43% 257.66% -3.47% -93.61% 1,227.80% 50.81% -105.75% 1,858.64% 33.11% 27.89% 9.83%
Net Income Growth
5.86% 267.25% -4.19% -93.07% 1,161.29% 52.79% -85.79% 581.19% 37.56% 34.02% 11.87%
EPS Growth
-9.09% 200.00% 0.00% -93.33% 1,200.00% 50.00% -85.90% 572.73% 37.84% 32.35% 11.11%
Operating Cash Flow Growth
97.79% 162.31% 22.97% -63.68% 115.93% 38.73% -43.15% 93.52% -10.80% 34.08% 90.30%
Free Cash Flow Firm Growth
0.00% 368.92% -1.09% -98.66% 6,321.75% 46.31% -108.82% 1,466.98% -29.77% -69.70% 547.14%
Invested Capital Growth
29.45% 40.88% 25.13% 6.12% 14.85% 22.54% 1.43% 2.83% 62.44% 88.61% 16.71%
Revenue Q/Q Growth
0.00% 19.77% -7.96% 3.20% 5.67% 7.09% -6.88% 8.64% 5.94% 4.11% 2.72%
EBITDA Q/Q Growth
0.00% 42.97% -15.59% -12.63% 11.72% 5.10% -69.32% 28.54% 3.12% 9.10% 2.67%
EBIT Q/Q Growth
0.00% 37.05% -14.12% -25.70% 15.77% 5.58% -157.50% 33.15% 10.90% 4.71% 2.81%
NOPAT Q/Q Growth
0.00% 39.78% -15.25% -66.86% 31.24% 18.79% -117.18% 53.92% -4.34% 5.33% 3.46%
Net Income Q/Q Growth
0.00% 39.55% -14.91% -65.70% 31.87% 18.96% -65.54% 53.63% -1.68% 5.30% 3.26%
EPS Q/Q Growth
0.00% 39.53% -13.04% -66.67% 33.33% 18.18% -65.63% 54.17% -1.92% 4.65% 3.45%
Operating Cash Flow Q/Q Growth
-31.46% 22.04% 17.68% -19.41% 40.90% 4.14% -19.98% 8.37% -3.16% 6.94% 8.81%
Free Cash Flow Firm Q/Q Growth
0.00% 0.00% -6.42% -93.79% 91.61% 0.72% -155.53% 5.50% -13.57% 37.40% -3.72%
Invested Capital Q/Q Growth
0.00% 5.73% -9.04% -4.90% -15.02% 0.71% -15.24% 12.80% 10.81% 6.51% 9.06%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
78.25% 81.51% 81.06% 75.87% 76.31% 77.11% 74.33% 76.65% 77.45% 76.50% 76.94%
EBITDA Margin
20.23% 39.38% 36.65% 11.72% 23.99% 26.70% 2.28% 26.89% 31.61% 34.32% 34.26%
Operating Margin
19.59% 36.44% 33.60% 5.57% 19.72% 22.45% -2.38% 23.48% 29.32% 30.56% 29.99%
EBIT Margin
19.28% 36.83% 33.70% 6.05% 20.36% 23.48% -1.94% 23.52% 30.36% 33.16% 33.14%
Profit (Net Income) Margin
13.10% 23.83% 22.20% 2.17% 20.71% 25.00% 4.32% 22.30% 24.07% 26.22% 26.26%
Tax Burden Percent
67.95% 64.72% 65.87% 35.79% 101.71% 106.50% -221.92% 94.81% 79.28% 79.09% 79.23%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
32.05% 35.28% 34.13% 64.21% -1.71% -6.50% 0.00% 5.19% 20.72% 20.91% 20.77%
Return on Invested Capital (ROIC)
66.73% 175.63% 128.76% 7.19% 86.26% 109.36% -5.67% 97.57% 97.62% 69.89% 54.20%
ROIC Less NNEP Spread (ROIC-NNEP)
67.06% 175.27% 128.68% 7.03% 85.62% 108.31% -9.53% 97.54% 96.89% 67.19% 50.31%
Return on Net Nonoperating Assets (RNNOA)
-51.15% -147.12% -106.16% -5.64% -69.43% -89.60% 8.01% -83.61% -80.03% -46.19% -29.89%
Return on Equity (ROE)
15.58% 28.51% 22.61% 1.54% 16.84% 19.76% 2.34% 13.96% 17.59% 23.70% 24.31%
Cash Return on Invested Capital (CROIC)
41.06% 141.69% 106.44% 1.25% 72.44% 89.10% -7.08% 94.78% 50.03% 8.49% 38.78%
Operating Return on Assets (OROA)
19.92% 39.74% 30.24% 3.66% 14.17% 15.70% -0.90% 12.78% 19.22% 24.47% 25.49%
Return on Assets (ROA)
13.54% 25.72% 19.92% 1.31% 14.42% 16.72% 1.99% 12.12% 15.24% 19.35% 20.20%
Return on Common Equity (ROCE)
15.58% 28.51% 22.61% 1.54% 16.84% 19.76% 2.34% 13.96% 17.59% 23.70% 24.31%
Return on Equity Simple (ROE_SIMPLE)
9.81% 23.58% 22.62% 1.52% 15.03% 17.35% 2.23% 12.92% 17.41% 24.07% 22.15%
Net Operating Profit after Tax (NOPAT)
2.08 7.45 7.19 0.46 6.11 9.21 -0.53 9.31 12 16 17
NOPAT Margin
13.31% 23.58% 22.13% 1.99% 20.06% 23.91% -1.67% 22.26% 23.24% 24.17% 23.76%
Net Nonoperating Expense Percent (NNEP)
-0.33% 0.35% 0.08% 0.15% 0.65% 1.05% 3.87% 0.03% 0.73% 2.70% 3.89%
Return On Investment Capital (ROIC_SIMPLE)
- - - - - - - - - 22.19% 20.05%
Cost of Revenue to Revenue
21.75% 18.49% 18.94% 24.13% 23.69% 22.89% 25.67% 23.35% 22.55% 23.50% 23.06%
SG&A Expenses to Revenue
30.77% 24.59% 27.07% 39.00% 28.62% 27.13% 38.68% 23.37% 20.07% 23.07% 21.76%
R&D to Revenue
6.83% 5.58% 4.15% 7.46% 4.98% 3.72% 6.00% 4.56% 4.27% 4.36% 3.87%
Operating Expenses to Revenue
58.66% 45.07% 47.46% 70.30% 56.58% 54.66% 76.71% 53.17% 48.13% 45.95% 46.95%
Earnings before Interest and Taxes (EBIT)
3.02 12 11 1.40 6.20 9.04 -0.62 9.84 16 22 24
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
3.17 12 12 2.71 7.30 10 0.72 11 17 23 25
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
6.22 9.05 3.47 4.52 5.94 4.50 4.24 7.36 4.59 8.27 8.00
Price to Tangible Book Value (P/TBV)
6.29 9.10 3.58 4.65 6.06 4.57 4.31 7.47 4.72 8.58 8.30
Price to Revenue (P/Rev)
8.30 9.15 3.41 6.45 8.18 6.49 8.21 12.70 6.34 9.01 9.49
Price to Earnings (P/E)
63.36 38.37 15.35 297.98 39.51 25.96 190.30 56.95 26.33 34.37 36.13
Dividend Yield
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 3.72% 3.26% 1.70%
Earnings Yield
1.58% 2.61% 6.52% 0.34% 2.53% 3.85% 0.53% 1.76% 3.80% 2.91% 2.77%
Enterprise Value to Invested Capital (EV/IC)
31.95 52.79 13.70 18.60 28.37 21.97 22.17 48.45 17.81 18.26 18.58
Enterprise Value to Revenue (EV/Rev)
7.19 8.29 2.62 5.31 7.05 5.29 6.57 11.21 5.25 8.25 8.78
Enterprise Value to EBITDA (EV/EBITDA)
35.55 21.06 7.14 45.31 29.40 19.81 288.85 41.68 16.61 24.04 25.61
Enterprise Value to EBIT (EV/EBIT)
37.30 22.52 7.77 87.78 34.64 22.54 0.00 47.64 17.30 24.89 26.48
Enterprise Value to NOPAT (EV/NOPAT)
54.02 35.16 11.82 266.53 35.16 22.13 0.00 50.35 22.59 34.15 36.93
Enterprise Value to Operating Cash Flow (EV/OCF)
38.60 34.25 9.04 35.88 29.11 19.92 35.85 41.62 27.87 40.18 25.08
Enterprise Value to Free Cash Flow (EV/FCFF)
87.80 43.58 14.30 1,534.96 41.86 27.16 0.00 51.83 44.07 281.19 51.61
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.76 -0.84 -0.82 -0.80 -0.81 -0.83 -0.84 -0.86 -0.83 -0.69 -0.59
Leverage Ratio
1.15 1.11 1.14 1.18 1.17 1.18 1.18 1.15 1.15 1.22 1.20
Compound Leverage Factor
1.15 1.11 1.14 1.18 1.17 1.18 1.18 1.15 1.15 1.22 1.20
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
34.65 55.90 16.09 17.09 25.81 16.13 18.30 32.46 20.11 20.02 39.42
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
9.74 11.76 9.25 8.61 9.50 10.06 12.96 11.18 9.06 4.65 8.84
Quick Ratio
8.49 10.68 8.04 7.39 8.23 9.14 11.50 9.91 8.33 3.80 7.38
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
1.28 6.01 5.95 0.08 5.13 7.50 -0.66 9.04 6.35 1.92 12
Operating Cash Flow to CapEx
480.99% 2,429.60% 617.09% 414.17% 2,786.93% 2,106.32% 913.63% 1,517.76% 535.61% 168.16% 290.63%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
1.03 1.08 0.90 0.61 0.70 0.67 0.46 0.54 0.63 0.74 0.77
Accounts Receivable Turnover
7.94 10.85 8.51 6.11 7.62 6.70 5.34 8.61 5.79 5.14 6.43
Inventory Turnover
1.96 2.59 1.96 1.38 1.74 2.29 2.15 2.37 2.49 1.69 1.45
Fixed Asset Turnover
27.90 37.16 27.52 13.88 16.28 19.63 15.20 19.96 23.85 11.22 5.61
Accounts Payable Turnover
6.44 7.15 5.79 6.27 10.09 9.98 9.87 13.56 9.31 8.43 9.00
Days Sales Outstanding (DSO)
45.96 33.64 42.90 59.73 47.90 54.50 68.29 42.39 63.04 70.98 56.76
Days Inventory Outstanding (DIO)
185.81 140.90 185.91 265.32 209.29 159.42 169.78 153.89 146.80 215.51 250.90
Days Payable Outstanding (DPO)
56.64 51.08 63.05 58.24 36.17 36.56 37.00 26.91 39.20 43.32 40.55
Cash Conversion Cycle (CCC)
175.13 123.46 165.76 266.81 221.02 177.36 201.07 169.36 170.63 243.17 267.11
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
3.52 4.96 6.21 6.59 7.57 9.27 9.41 9.67 16 30 35
Invested Capital Turnover
5.01 7.45 5.82 3.61 4.30 4.57 3.40 4.38 4.20 2.89 2.28
Increase / (Decrease) in Invested Capital
0.80 1.44 1.25 0.38 0.98 1.71 0.13 0.27 6.04 14 4.95
Enterprise Value (EV)
113 262 85 123 215 204 209 469 280 541 643
Market Capitalization
130 289 111 149 249 250 261 531 338 591 695
Book Value per Share
$1.93 $2.88 $2.98 $3.12 $3.84 $4.83 $5.00 $5.85 $5.86 $5.67 $6.85
Tangible Book Value per Share
$1.91 $2.87 $2.89 $3.04 $3.76 $4.76 $4.92 $5.76 $5.70 $5.47 $6.61
Total Capital
21 32 32 33 42 56 61 72 74 71 87
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-17 -27 -26 -26 -34 -46 -52 -63 -58 -50 -52
Capital Expenditures (CapEx)
0.61 0.31 1.52 0.82 0.26 0.49 0.64 0.74 1.87 8.01 8.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)
2.52 4.09 4.52 4.69 5.47 6.85 6.84 6.92 11 9.91 14
Debt-free Net Working Capital (DFNWC)
20 31 30 31 40 53 59 69 69 60 67
Net Working Capital (NWC)
20 31 30 31 40 53 59 69 69 60 67
Net Nonoperating Expense (NNE)
0.03 -0.08 -0.02 -0.04 -0.20 -0.42 -1.90 -0.02 -0.44 -1.35 -1.83
Net Nonoperating Obligations (NNO)
-17 -27 -26 -26 -34 -46 -52 -63 -58 -42 -52
Total Depreciation and Amortization (D&A)
0.15 0.81 0.96 1.31 1.11 1.24 1.34 1.41 0.67 0.77 0.82
Debt-free, Cash-free Net Working Capital to Revenue
16.12% 12.96% 13.89% 20.31% 17.99% 17.80% 21.57% 16.55% 20.59% 15.12% 19.79%
Debt-free Net Working Capital to Revenue
127.08% 98.33% 92.92% 134.43% 130.92% 137.87% 185.45% 166.02% 129.33% 91.02% 91.11%
Net Working Capital to Revenue
127.08% 98.33% 92.92% 134.43% 130.92% 137.87% 185.45% 166.02% 129.33% 91.02% 91.11%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.23 $0.68 $0.67 $0.05 $0.59 $0.85 $0.11 $0.76 $1.02 $1.36 $1.52
Adjusted Weighted Average Basic Shares Outstanding
8.74M 11.00M 10.82M 10.64M 10.76M 11.28M 12.12M 12.35M 12.56M 12.60M 12.67M
Adjusted Diluted Earnings per Share
$0.20 $0.60 $0.60 $0.04 $0.52 $0.78 $0.11 $0.74 $1.02 $1.35 $1.50
Adjusted Weighted Average Diluted Shares Outstanding
10.22M 12.56M 11.99M 11.72M 12.11M 12.28M 12.44M 12.59M 12.64M 12.72M 12.78M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
10.97M 11.03M 10.74M 10.60M 11.00M 11.92M 12.31M 12.56M 12.59M 12.66M 12.72M
Normalized Net Operating Profit after Tax (NOPAT)
2.08 7.45 7.19 0.90 4.20 6.05 -0.53 9.31 12 16 17
Normalized NOPAT Margin
13.31% 23.58% 22.13% 3.90% 13.81% 15.72% -1.67% 22.26% 23.24% 24.17% 23.76%
Pre Tax Income Margin
19.28% 36.83% 33.70% 6.05% 20.36% 23.48% -1.94% 23.52% 30.36% 33.16% 33.14%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 97.90% 76.91% 71.11%
Augmented Payout Ratio
99.71% 0.00% 138.19% 363.88% 0.00% 0.00% 0.00% 0.00% 97.90% 76.91% 71.11%

Quarterly Metrics And Ratios for iRadimed

This table displays calculated financial ratios and metrics derived from iRadimed's official financial filings.

Metric Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025
Period end date 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025
Growth Metrics
- - - - - - - - - - -
Revenue Growth
25.19% 25.70% 26.80% 23.10% 17.42% 13.72% 11.15% 11.04% 11.10% 10.87% 13.84%
EBITDA Growth
14.59% 29.72% 17.37% 41.20% 46.78% 20.68% 17.91% 0.26% 11.08% 12.25% 16.49%
EBIT Growth
51.07% 42.15% 26.77% 51.23% 20.79% 20.55% 18.32% 0.15% 11.66% 13.39% 16.88%
NOPAT Growth
-14.54% 25.58% 21.18% 39.71% 24.09% 19.38% 12.36% -2.46% 14.13% 14.32% 21.59%
Net Income Growth
-5.63% 36.97% 28.97% 47.86% 23.58% 21.45% 17.26% -0.35% 13.37% 13.32% 17.81%
EPS Growth
-6.45% 35.00% 26.92% 48.15% 20.69% 18.52% 15.15% 0.00% 14.29% 15.63% 18.42%
Operating Cash Flow Growth
-9.72% 225.77% 114.36% -64.64% 28.75% -16.42% 88.93% 554.54% 53.02% 10.53% 16.69%
Free Cash Flow Firm Growth
-175.03% -637.03% -221.50% -296.70% -260.61% 16.66% 35.47% 107.42% 97.49% 21.80% -35.34%
Invested Capital Growth
62.44% 85.86% 68.66% 96.22% 88.61% 43.74% 34.35% 13.98% 16.71% 28.16% 32.66%
Revenue Q/Q Growth
10.86% 4.11% 4.23% 2.32% 5.74% 0.84% 1.88% 2.21% 5.80% 0.63% 4.61%
EBITDA Q/Q Growth
-14.17% 13.00% 21.04% 20.28% -10.78% -7.09% 18.26% 2.28% -1.16% -6.11% 22.72%
EBIT Q/Q Growth
11.00% -7.52% 21.81% 20.95% -11.34% -7.71% 19.56% 2.38% -1.15% -6.29% 23.24%
NOPAT Q/Q Growth
-0.59% -5.55% 24.77% 19.26% -11.71% -9.14% 17.44% 3.53% 3.31% -8.99% 24.91%
Net Income Q/Q Growth
7.19% -7.28% 22.72% 21.23% -10.41% -8.88% 18.49% 3.03% 1.93% -8.93% 23.18%
EPS Q/Q Growth
7.41% -6.90% 22.22% 21.21% -12.50% -8.57% 18.75% 5.26% 0.00% -7.50% 21.62%
Operating Cash Flow Q/Q Growth
-22.84% 52.89% -24.37% -60.36% 180.93% -0.75% 70.96% 37.32% -34.32% -28.31% 80.48%
Free Cash Flow Firm Q/Q Growth
-20.11% -151.09% 19.11% -62.60% -9.19% 41.97% 37.36% 118.69% -136.88% -1,710.86% -8.40%
Invested Capital Q/Q Growth
10.81% 37.24% 7.48% 20.05% 6.51% 4.59% 0.46% 1.85% 9.06% 14.86% 3.98%
Profitability Metrics
- - - - - - - - - - -
Gross Margin
75.49% 75.74% 75.55% 77.78% 76.86% 76.07% 78.14% 77.44% 76.13% 76.08% 78.17%
EBITDA Margin
26.98% 29.29% 34.01% 39.98% 33.73% 31.08% 36.08% 36.10% 33.73% 31.47% 36.92%
Operating Margin
28.62% 25.89% 30.77% 35.78% 29.57% 26.98% 31.39% 31.59% 29.91% 27.84% 33.26%
EBIT Margin
31.65% 28.11% 32.85% 38.83% 32.56% 29.80% 34.97% 35.02% 32.72% 30.47% 35.90%
Profit (Net Income) Margin
24.72% 22.01% 25.91% 30.70% 26.01% 23.51% 27.34% 27.55% 26.54% 24.03% 28.29%
Tax Burden Percent
78.10% 78.31% 78.89% 79.07% 79.90% 78.89% 78.18% 78.67% 81.12% 78.84% 78.80%
Interest Burden Percent
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Effective Tax Rate
21.90% 21.69% 21.11% 20.93% 20.10% 21.11% 21.82% 21.33% 18.88% 21.16% 21.20%
Return on Invested Capital (ROIC)
93.87% 69.05% 78.74% 84.83% 68.31% 54.83% 62.78% 59.53% 55.36% 46.65% 56.18%
ROIC Less NNEP Spread (ROIC-NNEP)
93.29% 68.48% 78.20% 84.06% 67.47% 53.94% 61.72% 58.53% 54.42% 45.80% 55.34%
Return on Net Nonoperating Assets (RNNOA)
-77.05% -50.58% -56.80% -59.60% -46.39% -33.75% -39.17% -36.47% -32.33% -26.31% -32.30%
Return on Equity (ROE)
16.82% 18.47% 21.94% 25.24% 21.92% 21.07% 23.61% 23.06% 23.02% 20.34% 23.88%
Cash Return on Invested Capital (CROIC)
50.03% 18.52% 23.18% 6.67% 8.49% 26.72% 33.05% 43.45% 38.78% 26.05% 24.08%
Operating Return on Assets (OROA)
20.03% 21.45% 25.03% 29.29% 24.03% 24.65% 28.35% 27.50% 25.16% 24.14% 28.38%
Return on Assets (ROA)
15.65% 16.79% 19.75% 23.16% 19.20% 19.45% 22.17% 21.63% 20.41% 19.03% 22.37%
Return on Common Equity (ROCE)
16.82% 18.47% 21.94% 25.24% 21.92% 21.07% 23.61% 23.06% 23.02% 20.34% 23.88%
Return on Equity Simple (ROE_SIMPLE)
0.00% 21.37% 21.29% 21.90% 0.00% 23.55% 23.40% 22.33% 0.00% 21.97% 0.00%
Net Operating Profit after Tax (NOPAT)
3.32 3.14 3.92 4.67 4.12 3.75 4.40 4.55 4.71 4.28 5.35
NOPAT Margin
22.35% 20.28% 24.27% 28.29% 23.62% 21.29% 24.54% 24.85% 24.27% 21.95% 26.21%
Net Nonoperating Expense Percent (NNEP)
0.58% 0.57% 0.54% 0.78% 0.84% 0.89% 1.06% 1.01% 0.94% 0.85% 0.84%
Return On Investment Capital (ROIC_SIMPLE)
- - - - 5.77% - - - 5.42% 4.76% 5.67%
Cost of Revenue to Revenue
24.51% 24.26% 24.45% 22.22% 23.14% 23.93% 21.86% 22.56% 23.87% 23.92% 21.83%
SG&A Expenses to Revenue
18.14% 25.33% 20.54% 21.90% 24.49% 22.68% 22.90% 21.65% 19.98% 23.63% 20.97%
R&D to Revenue
4.07% 19.39% 5.96% 2.74% -8.91% 21.75% 4.47% 3.49% -12.56% 3.20% 4.30%
Operating Expenses to Revenue
46.87% 49.85% 44.78% 42.00% 47.29% 49.09% 46.75% 45.85% 46.21% 48.24% 44.92%
Earnings before Interest and Taxes (EBIT)
4.70 4.35 5.30 6.41 5.68 5.24 6.27 6.42 6.34 5.95 7.33
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)
4.01 4.53 5.49 6.60 5.89 5.47 6.47 6.62 6.54 6.14 7.53
Valuation Ratios
- - - - - - - - - - -
Price to Book Value (P/BV)
4.59 7.54 8.53 7.34 8.27 7.27 6.96 7.64 8.00 7.41 8.06
Price to Tangible Book Value (P/TBV)
4.72 7.81 8.84 7.60 8.58 7.53 7.21 7.91 8.30 7.69 8.36
Price to Revenue (P/Rev)
6.34 8.60 9.84 8.70 9.01 8.17 7.98 8.94 9.49 8.88 9.79
Price to Earnings (P/E)
26.33 35.30 40.10 33.54 34.37 30.87 29.75 34.21 36.13 33.73 36.80
Dividend Yield
3.72% 2.72% 2.25% 2.42% 3.26% 3.50% 1.44% 1.55% 1.70% 1.18% 1.07%
Earnings Yield
3.80% 2.83% 2.49% 2.98% 2.91% 3.24% 3.36% 2.92% 2.77% 2.97% 2.72%
Enterprise Value to Invested Capital (EV/IC)
17.81 20.52 23.43 18.00 18.26 16.39 16.25 18.46 18.58 15.53 17.12
Enterprise Value to Revenue (EV/Rev)
5.25 7.84 9.07 7.95 8.25 7.51 7.28 8.21 8.78 8.21 9.11
Enterprise Value to EBITDA (EV/EBITDA)
16.61 24.74 29.04 24.28 24.04 21.68 20.72 23.95 25.61 23.95 26.36
Enterprise Value to EBIT (EV/EBIT)
17.30 25.33 29.21 24.13 24.89 22.45 21.44 24.79 26.48 24.70 27.16
Enterprise Value to NOPAT (EV/NOPAT)
22.59 33.96 39.60 33.30 34.15 30.88 29.88 34.80 36.93 34.39 37.44
Enterprise Value to Operating Cash Flow (EV/OCF)
27.87 33.37 35.88 39.78 40.18 40.00 31.97 24.86 25.08 23.70 26.06
Enterprise Value to Free Cash Flow (EV/FCFF)
44.07 144.13 126.94 357.68 281.19 72.36 56.38 45.27 51.61 66.98 81.09
Leverage & Solvency
- - - - - - - - - - -
Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage
-0.83 -0.74 -0.73 -0.71 -0.69 -0.63 -0.63 -0.62 -0.59 -0.57 -0.58
Leverage Ratio
1.15 1.17 1.17 1.16 1.22 1.17 1.15 1.15 1.20 1.14 1.13
Compound Leverage Factor
1.15 1.17 1.17 1.16 1.22 1.17 1.15 1.15 1.20 1.14 1.13
Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital
100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score
19.66 28.31 30.95 28.19 19.45 30.51 35.04 37.97 38.82 36.83 40.11
Noncontrolling Interest Sharing Ratio
0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios
- - - - - - - - - - -
Current Ratio
9.06 9.07 8.71 9.13 4.65 9.44 9.87 9.21 8.84 8.87 8.78
Quick Ratio
8.33 8.04 7.50 7.55 3.80 7.64 8.11 7.70 7.38 7.44 7.25
Cash Flow Metrics
- - - - - - - - - - -
Free Cash Flow to Firm (FCFF)
-2.72 -6.82 -5.52 -8.97 -9.80 -5.69 -3.56 0.67 -0.25 -4.45 -4.82
Operating Cash Flow to CapEx
644.27% 70.86% 928.79% 317.22% 618.27% 811.01% 522.81% 227.24% 195.87% 109.57% 274.33%
Free Cash Flow to Firm to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios
- - - - - - - - - - -
Asset Turnover
0.63 0.76 0.76 0.75 0.74 0.83 0.81 0.79 0.77 0.79 0.79
Accounts Receivable Turnover
5.79 6.26 6.15 5.37 5.14 5.51 6.03 6.16 6.43 5.84 6.79
Inventory Turnover
2.49 2.41 2.14 1.77 1.69 1.67 1.55 1.42 1.45 1.49 1.54
Fixed Asset Turnover
23.85 10.46 10.93 11.27 11.22 7.48 7.24 6.19 5.61 5.04 4.65
Accounts Payable Turnover
9.31 8.88 8.42 8.01 8.43 10.43 8.62 7.79 9.00 8.95 11.84
Days Sales Outstanding (DSO)
63.04 58.32 59.33 67.91 70.98 66.22 60.50 59.25 56.76 62.49 53.77
Days Inventory Outstanding (DIO)
146.80 151.44 170.51 205.64 215.51 218.72 236.09 256.56 250.90 244.59 237.47
Days Payable Outstanding (DPO)
39.20 41.11 43.35 45.57 43.32 35.00 42.33 46.83 40.55 40.77 30.84
Cash Conversion Cycle (CCC)
170.63 168.66 186.49 227.99 243.17 249.94 254.26 268.98 267.11 266.31 260.40
Capital & Investment Metrics
- - - - - - - - - - -
Invested Capital
16 22 23 28 30 31 31 32 35 40 41
Invested Capital Turnover
4.20 3.41 3.24 3.00 2.89 2.58 2.56 2.40 2.28 2.13 2.14
Increase / (Decrease) in Invested Capital
6.04 9.96 9.43 14 14 9.43 7.96 3.89 4.95 8.73 10
Enterprise Value (EV)
280 443 543 501 541 508 506 585 643 617 707
Market Capitalization
338 485 589 548 591 553 555 637 695 667 760
Book Value per Share
$5.86 $5.11 $5.48 $5.92 $5.67 $6.01 $6.29 $6.59 $6.85 $7.08 $7.42
Tangible Book Value per Share
$5.70 $4.93 $5.29 $5.72 $5.47 $5.80 $6.07 $6.36 $6.61 $6.83 $7.15
Total Capital
74 64 69 75 71 76 80 83 87 90 94
Total Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt
-58 -43 -46 -47 -50 -45 -49 -52 -52 -50 -53
Capital Expenditures (CapEx)
0.47 6.56 0.38 0.44 0.63 0.48 1.27 4.01 3.06 3.92 2.82
Debt-free, Cash-free Net Working Capital (DFCFNWC)
11 12 13 17 9.91 19 18 15 14 16 16
Debt-free Net Working Capital (DFNWC)
69 55 59 64 60 64 66 66 67 67 69
Net Working Capital (NWC)
69 55 59 64 60 64 66 66 67 67 69
Net Nonoperating Expense (NNE)
-0.35 -0.27 -0.26 -0.40 -0.42 -0.39 -0.50 -0.50 -0.44 -0.41 -0.42
Net Nonoperating Obligations (NNO)
-58 -43 -46 -47 -42 -45 -49 -52 -52 -50 -53
Total Depreciation and Amortization (D&A)
-0.69 0.18 0.19 0.19 0.21 0.23 0.20 0.20 0.19 0.19 0.21
Debt-free, Cash-free Net Working Capital to Revenue
20.59% 20.84% 21.18% 27.48% 15.12% 28.28% 25.31% 20.34% 19.79% 21.73% 20.05%
Debt-free Net Working Capital to Revenue
129.33% 96.59% 97.71% 101.71% 91.02% 94.95% 95.16% 92.87% 91.11% 88.70% 88.31%
Net Working Capital to Revenue
129.33% 96.59% 97.71% 101.71% 91.02% 94.95% 95.16% 92.87% 91.11% 88.70% 88.31%
Earnings Adjustments
- - - - - - - - - - -
Adjusted Basic Earnings per Share
$0.29 $0.27 $0.33 $0.40 $0.36 $0.33 $0.39 $0.40 $0.40 $0.37 $0.45
Adjusted Weighted Average Basic Shares Outstanding
12.56M 12.59M 12.60M 12.60M 12.60M 12.66M 12.66M 12.67M 12.67M 12.71M 12.72M
Adjusted Diluted Earnings per Share
$0.29 $0.27 $0.33 $0.40 $0.35 $0.32 $0.38 $0.40 $0.40 $0.37 $0.45
Adjusted Weighted Average Diluted Shares Outstanding
12.64M 12.69M 12.72M 12.74M 12.72M 12.75M 12.76M 12.78M 12.78M 12.83M 12.84M
Adjusted Basic & Diluted Earnings per Share
$0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding
12.59M 12.59M 12.60M 12.61M 12.66M 12.66M 12.67M 12.67M 12.72M 12.72M 12.72M
Normalized Net Operating Profit after Tax (NOPAT)
3.32 3.14 3.92 4.67 4.12 3.75 4.40 4.55 4.71 4.28 5.35
Normalized NOPAT Margin
22.35% 20.28% 24.27% 28.29% 23.62% 21.29% 24.54% 24.85% 24.27% 21.95% 26.21%
Pre Tax Income Margin
31.65% 28.11% 32.85% 38.83% 32.56% 29.80% 34.97% 35.02% 32.72% 30.47% 35.90%
Debt Service Ratios
- - - - - - - - - - -
EBIT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense
0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios
- - - - - - - - - - -
Dividend Payout Ratio
97.90% 96.18% 90.03% 80.99% 76.91% 44.50% 52.97% 63.22% 71.11% 39.74% 39.33%
Augmented Payout Ratio
97.90% 96.18% 90.03% 80.99% 76.91% 44.50% 52.97% 63.22% 71.11% 39.74% 39.33%

Key Financial Trends

iRadimed (NASDAQ:IRMD) Financial Summary - Q2 2025 and Prior Periods

iRadimed reported a solid set of financial results in Q2 2025, continuing a positive growth trend observed over the past several years. Key financial highlights and trends from the last four years are summarized below to help investors understand the company’s recent financial performance and position.

  • Increasing Revenue: Operating revenue for Q2 2025 was $20.41 million, up from $19.51 million in Q1 2025 and showing steady growth from $17.53 million in Q2 2024 and $14.86 million in Q4 2022.
  • Rising Net Income: Consolidated net income increased to $5.77 million in Q2 2025 from $4.69 million in Q1 2025, continuing an upward trend compared to $4.90 million in Q2 2024 and $3.67 million in Q4 2022.
  • Strong Earnings Per Share (EPS): Diluted EPS rose to $0.45 in Q2 2025, up from $0.37 in Q1 2025. EPS has shown steady growth compared to $0.39 in Q2 2024 and $0.29 in Q4 2022, indicating improving profitability.
  • Robust Cash Flow from Operations: Net cash from operating activities surged to $7.75 million in Q2 2025, a significant increase from $4.29 million in Q1 2025 and $6.64 million in Q2 2024, reflecting healthy operational cash generation.
  • Prudent Capital Expenditures: Investment in property, plant, and equipment was $2.82 million in Q2 2025, lower than prior quarters (e.g., $3.92 million in Q1 2025 and $3.06 million in Q4 2024), suggesting a controlled investment approach.
  • Dividend Payments Maintained: Quarterly dividend payments remained consistent around $2.16 million, demonstrating the company's commitment to returning capital to shareholders.
  • Increasing Shareholders’ Equity: Total common equity grew to $94.30 million by Q2 2025 from $90.05 million in Q1 2025 and $79.67 million in Q2 2024, indicating strengthening financial stability.
  • Stable Total Assets: Total assets increased moderately to $106.4 million in Q2 2025 from $101.7 million in Q1 2025.
  • Moderate Increase in Liabilities: Total liabilities were $12.15 million in Q2 2025, up slightly from $11.68 million in Q1 2025, yet remain low relative to equity levels.
  • Rising Income Tax Expense: Income tax expenses increased in Q2 2025 to $1.55 million from $1.26 million in Q1 2025, reflecting higher pre-tax earnings but impacting net profitability.

Financial Trends and Insights:

Over the past four years, iRadimed has consistently increased revenues and net income, accompanied by steady EPS growth. The company’s operating cash flows have been robust, funding capital expenditures and dividend payments without significant reliance on financing activities, which have consistently been negative due to dividends and other financing outflows.

The balance sheet shows growing equity and manageable liabilities, enhancing the company’s financial resilience. Capital spending has been substantial but well-managed, primarily supporting growth initiatives without excessive expansion.

Investors should note the increasing income tax burden correlating with earnings growth, which could affect net income margin. The company’s maintained dividend payments indicate confidence in cash flow sustainability.

Overall, iRadimed demonstrates solid financial health and operational efficiency, with positive earnings momentum and prudent capital management supporting long-term shareholder value.

08/08/25 09:04 PMAI Generated. May Contain Errors.

Frequently Asked Questions About iRadimed's Financials

When does iRadimed's financial year end?

According to the most recent income statement we have on file, iRadimed's fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has iRadimed's net income changed over the last 10 years?

iRadimed's net income appears to be on an upward trend, with a most recent value of $19.23 million in 2024, rising from $2.05 million in 2014. The previous period was $17.19 million in 2023. Find out what analysts predict for iRadimed in the coming months.

What is iRadimed's operating income?
iRadimed's total operating income in 2024 was $21.96 million, based on the following breakdown:
  • Total Gross Profit: $56.35 million
  • Total Operating Expenses: $34.39 million
How has iRadimed's revenue changed over the last 10 years?

Over the last 10 years, iRadimed's total revenue changed from $15.65 million in 2014 to $73.24 million in 2024, a change of 367.9%.

How much debt does iRadimed have?

iRadimed's total liabilities were at $11.51 million at the end of 2024, a 44.5% decrease from 2023, and a 375.7% increase since 2014.

How much cash does iRadimed have?

In the past 10 years, iRadimed's cash and equivalents has ranged from $9.45 million in 2014 to $62.00 million in 2021, and is currently $52.23 million as of their latest financial filing in 2024.

How has iRadimed's book value per share changed over the last 10 years?

Over the last 10 years, iRadimed's book value per share changed from 1.93 in 2014 to 6.85 in 2024, a change of 254.6%.



This page (NASDAQ:IRMD) was last updated on 8/8/2025 by MarketBeat.com Staff
From Our Partners